TY - JOUR T1 - Correction to “Rimonabant, a Cannabinoid Receptor Type 1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating Liver Kinase B1 and AMP-Activated Protein Kinase Axis Downstream of Gα<sub>i/o</sub> Inhibition” JF - Molecular Pharmacology JO - Mol Pharmacol SP - 561 LP - 562 DO - 10.1124/mol.82.3.561 VL - 82 IS - 3 A2 - , Y1 - 2012/09/01 UR - http://molpharm.aspetjournals.org/content/82/3/561.abstract N2 - ER -